名臣健康(002919.SZ)擬2.19億元收購喀什奧術100%股權 與現有遊戲業務形成產業協同
格隆匯10月31日丨 名臣健康(002919.SZ)公佈,公司擬以2.19億元收購喀什奧術網絡科技有限公司(以下簡稱"喀什奧術")100%股權。
喀什奧術設立時間較短,目前尚未盈利。主要承接了其母公司廣州心源互動科技有限公司的部分遊戲開發團隊和相關遊戲開發項目,並與行業知名公司建立了合作關係。
公司此次收購旨在擴充產品品類,增加儲備產品,培育新的業績增長點,同時大幅增厚人才儲備,與現有遊戲業務形成產業協同,為公司長期深耕遊戲行業進一步夯實基礎。
此次交易完成後,喀什奧術將成為公司的全資子公司,公司能否對喀什奧術實施有效整合,既保證上市公司對目標公司的控制力,又保持、增強其原有的競爭優勢,具有一定的不確定性,進而可能影響此次交易的最終效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.